<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phencyclidine (PCP) intoxication in children and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phencyclidine (PCP) intoxication in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Phencyclidine (PCP) intoxication in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael D Levine, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>An overview of phencyclidine (PCP) intoxication in children and adolescents will be reviewed here. The clinical manifestations and management of PCP intoxication in adults and <a class="drug drug_pediatric" data-topicid="13398" href="/d/drug information/13398.html" rel="external">ketamine</a> poisoning are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/298.html" rel="external">"Ketamine poisoning"</a>.)</p><p></p><p class="headingAnchor" id="H375894369"><span class="h1">BACKGROUND</span><span class="headingEndMark"> — </span>PCP, ie, 1-(1-phenylcyclohexyl) piperidine hydrochloride, is a synthetic hallucinogen that has a variety of street names, including "angel dust," "dust," and "sherms"  (<a class="graphic graphic_table graphicRef78468" href="/d/graphic/78468.html" rel="external">table 1</a>). These names, along with others, reflect its unpredictable and volatile effects. It was patented in the 1950s as a dissociative anesthetic agent called Sernyl but was later withdrawn from the market due to adverse effects, including severe agitation, confusion, hallucinations, and prolonged periods of decreased consciousness [<a href="#rid1">1,2</a>]. The recreational use of PCP gained popularity during the 1960s due to its hallucinogenic effects and ease of synthesis. In April of 1979, all legal manufacturing of PCP in the United States was terminated [<a href="#rid3">3</a>].</p><p>In the early 1970s, a laboratory investigation of PCP derivatives led to the discovery of <a class="drug drug_pediatric" data-topicid="13398" href="/d/drug information/13398.html" rel="external">ketamine</a>. Ketamine is 5 to 10 percent as potent as PCP and is now used clinically to induce dissociative anesthesia. Ketamine is also abused as a recreational drug. (See  <a class="medical medical_review" href="/d/html/298.html" rel="external">"Ketamine poisoning"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>According to the National Institute on Drug Abuse (NIDA) Monitoring the Future study, which tracks reported illicit drug use among high-school students, the recreational use of PCP in the prior year by United States high school seniors decreased from 7 percent in 1979 to 1.3 percent in 2013, the last year the study inquired about PCP use [<a href="#rid4">4</a>]. However, almost 100,000 children between 11 and 21 years of age in the United States report having used PCP at least once in the prior year and approximately 1500 annual emergency department visits for PCP intoxication occur in this age group [<a href="#rid5">5</a>]. Between 2005 through 2011, emergency department visits for PCP intoxication among those age 12 to 17 years increased 184 percent [<a href="#rid6">6</a>]. Deaths due to PCP intoxication are uncommon; most fatalities are due to traumatic injury rather than direct drug effects [<a href="#rid7">7</a>].</p><p>PCP intoxication in children under six years of age is rare and typically occurs as an inadvertent oral or inhalational exposure due to caregiver drug use [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PHARMACOLOGY AND CELLULAR TOXICOLOGY</span><span class="headingEndMark"> — </span>PCP, or 1-(1-phenylcyclohexyl) piperidine hydrochloride, is an arylcyclohexylamine dissociative anesthetic with structural and pharmacologic properties similar to <a class="drug drug_pediatric" data-topicid="13398" href="/d/drug information/13398.html" rel="external">ketamine</a>. It is synthesized from piperidine and cyclohexanone and is manufactured illegally in underground laboratories and distributed in varying dosage forms, strengths, and purities [<a href="#rid9">9</a>]. Drug users may be exposed inadvertently to PCP because it is used as an additive in lysergic acid diethylamide (LSD), marijuana, and methamphetamine [<a href="#rid10">10</a>].</p><p>Compared with <a class="drug drug_pediatric" data-topicid="13398" href="/d/drug information/13398.html" rel="external">ketamine</a>, PCP is longer acting and more likely to cause seizures, confusion, and delirium. Synthetic derivatives of both PCP and ketamine, including <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a>, are used as recreational drugs. (See  <a class="medical medical_review" href="/d/html/298.html" rel="external">"Ketamine poisoning", section on 'Clinical presentation'</a>.)</p><p>PCP is available in white powder ("angel dust"), tablet ("peace pill"), crystal, and liquid ("whack") forms that can be ingested, inhaled, injected, or smoked. Young children can be exposed to PCP through secondhand smoke inhalation, PCP-impregnated cigarette butt ingestion, or inadvertent dermal exposure [<a href="#rid8">8,11-13</a>]. Adolescent use and pharmacologic effects are similar to adults. (See  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults", section on 'Pharmacology and cellular toxicology'</a> and  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults", section on 'Kinetics'</a>.)</p><p>PCP has three primary sites of action in the central nervous system [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The N-methyl-D-aspartate (NMDA) receptor complex – PCP has great affinity for NMDA receptor complexes in the hippocampus, neocortex, basal ganglia, and limbic system [<a href="#rid15">15</a>]. NMDA antagonism at these sites produces acute psychosis that mimics schizophrenia in humans and leads to excess excitatory neurotransmitters (eg, glutamate, glycine, aspartate) that can cause agitation and seizures. Animal studies also suggest that the developing brain is at greater risk for injury and cell death from excessive levels of these excitatory neurotransmitters [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The neuronal <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a>, <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a>, and serotonin reuptake complex – PCP inhibits reuptake of dopamine, norepinephrine, and serotonin [<a href="#rid16">16</a>]. This action likely explains the adrenergic effects (eg, tachycardia, hypertension) and dopaminergic effects (eg, dystonia, choreoathetosis, anticholinergic findings) seen in children with PCP intoxication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The sigma receptor complex – PCP binding to the sigma receptor has been demonstrated and may also explain, in part, psychotic, anticholinergic, and movement abnormalities seen in human intoxication [<a href="#rid17">17</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h1">KINETICS</span><span class="headingEndMark"> — </span>The kinetics of PCP in young infants and children has not been studied. The kinetics of PCP in adolescents is similar to adults and is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults", section on 'Kinetics'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FEATURES OF OVERDOSE</span><span class="headingEndMark"> — </span>PCP intoxication is a diagnosis that must be suspected clinically. PCP intoxication should be suspected in children with nystagmus, blank staring, strange behavior, altered mental status, agitation, choreoathetosis, seizures, acute psychosis, or a combination of these symptoms [<a href="#rid8">8,12,18</a>]. Duration of action is generally brief (four to eight hours).</p><p class="headingAnchor" id="H2410268"><span class="h2">History</span><span class="headingEndMark"> — </span>The history of unexpected exposure or overdose in young children under six years of age is rarely available [<a href="#rid12">12</a>]. Caregivers typically note an abrupt onset of altered behavior consistent with neurobehavioral effects of PCP [<a href="#rid8">8,11,12</a>].</p><p>Older children and adolescents usually are exposed to PCP through recreational use, although passive or inadvertent exposure (eg, being unaware of PCP in a marijuana cigarette) may also occur. In many instances, the patient is unable to provide a history. Sometimes, friends or emergency medical services personnel may provide useful details. It can be helpful to know the street names for PCP, which include angel dust, embalming fluid, fry, wets, killer weed, peace pill, horse tranquilizer, and hog  (<a class="graphic graphic_table graphicRef78468" href="/d/graphic/78468.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2411938"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>PCP intoxication produces a wide range of vital sign and neuropsychiatric findings.</p><p class="headingAnchor" id="H2412093"><span class="h3">General findings</span><span class="headingEndMark"> — </span>Physical examination should begin with an assessment of the patient's airway, breathing, circulation, and mental status. Respiratory depression occurs more commonly in children with PCP intoxication than in adults. Apnea may immediately precede or follow generalized seizures [<a href="#rid8">8,11</a>]. These episodes usually are brief and self-limited, but some patients require mechanical ventilation. Patients may also exhibit irregular breathing, with alternating episodes of apnea and tachypnea [<a href="#rid8">8,11</a>].</p><p class="headingAnchor" id="H2412100"><span class="h3">Vital signs</span><span class="headingEndMark"> — </span>Tachycardia and hypertension (both systolic and diastolic) are frequently seen. Hypertension is present in 30 percent of infants with PCP intoxication but is usually transient and asymptomatic. However, subarachnoid hemorrhage has been described [<a href="#rid8">8</a>]. Severe neuromuscular excitability can result in hyperthermia, while environmental exposure may cause hypothermia.</p><p class="headingAnchor" id="H2412164"><span class="h3">Eye findings</span><span class="headingEndMark"> — </span>Horizontal, vertical, or rotatory nystagmus is found in the majority of children and adolescents with PCP intoxication  (<a class="graphic graphic_table graphicRef74834" href="/d/graphic/74834.html" rel="external">table 2</a>). A stuporous blank stare is also often seen [<a href="#rid8">8,11,12</a>]. Classically, PCP has been listed as a cause of miosis. However, dilated pupils may also be seen. Rarely, oculogyric crisis may occur [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H2412295"><span class="h3">Neuropsychiatric findings</span><span class="headingEndMark"> — </span>Infants and young children who are exposed to PCP may present with seizures, irritability, lethargy, coma, fluctuations in level of consciousness, choreoathetosis, dystonia, and ataxia [<a href="#rid8">8,11,12</a>]. In one review of PCP intoxication in 28 children younger than five years of age, choreoathetosis was present in more than 50 percent of cases [<a href="#rid11">11</a>]. Opisthotonos and hyperreflexia are less commonly seen [<a href="#rid8">8,11,20</a>].</p><p>Older children and adolescents may also present with lethargy, coma, agitation, seizures, and ataxia. However, a significant number may be alert with bizarre behavior.</p><p>Psychomotor agitation is commonly seen in older children and adolescents with PCP intoxication. Similar to adults, these patients may demonstrate violent and unpredictable behavior that is exacerbated by decreased pain perception, hallucinations, paranoid delusions, and delusions of superhuman strength. Patients require a cautious approach during initial treatment to ensure staff safety while addressing the child's medical needs. (See  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults", section on 'Neuropsychiatric findings'</a>.)</p><p>Additional categorization of psychiatric symptoms is derived from studies in adults (see  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults", section on 'Neuropsychiatric findings'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Minor symptoms – Intermittent lethargy or stupor in combination with bizarre behavior, violence, agitation, or euphoria in patients who were otherwise alert and oriented</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Major symptoms – Psychosis with hallucinations, catatonia, coma, or acute brain syndrome (disorientation, confusion, lack of judgement, inappropriate affect, or memory loss)</p><p></p><p class="headingAnchor" id="H2412500"><span class="h3">Other findings</span><span class="headingEndMark"> — </span>Diaphoresis may accompany other findings of adrenergic excess (eg, tachycardia, hypertension, agitation). Hypersalivation is also frequently seen.</p><p>Injuries occur commonly in patients with PCP intoxication because the drug produces a dissociative state with violent and unpredictable behavior. The evaluation of patients with suspected trauma is complicated by the anesthetic effects of PCP, which can mask serious injuries [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H2412543"><span class="h3">Complications</span><span class="headingEndMark"> — </span>Fatalities in the setting of PCP intoxication are uncommon, and most are secondary to trauma. Other causes include hyperthermia, respiratory arrest, rhabdomyolysis with hyperkalemia, and intracranial hemorrhage.</p><p>Treating clinicians should be aware of the potential for multiple serious complications in children with PCP intoxication. These occur most often with large ingestions and may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Rhabdomyolysis</p><p class="bulletIndent1"><span class="glyph">●</span>Seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoglycemia</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged comatose state</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged psychosis</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Perinatal exposure</span><span class="headingEndMark"> — </span>PCP crosses the placenta and can be detected in umbilical cord blood [<a href="#rid22">22</a>], amniotic fluid [<a href="#rid23">23</a>], breast milk [<a href="#rid23">23</a>], and neonatal urine [<a href="#rid24">24,25</a>]. Although microcephaly [<a href="#rid25">25</a>] and dysmorphic facial features have been reported [<a href="#rid26">26</a>], teratologic effects of PCP on the developing fetus are not well described. Newborns of mothers who used PCP during pregnancy present with jitteriness, sleep problems during the first year, and other neurobehavioral abnormalities [<a href="#rid25">25,27,28</a>]. Similar to adults, neonates may have sudden changes in the level of consciousness, with alternating periods of lethargy and irritability [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H17"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The clinical picture of PCP intoxication shares features common to many other intoxications and medical conditions, especially those that cause acute psychosis. The differential diagnosis and approach to acute psychosis in the emergency department are provided in the tables and algorithm  (<a class="graphic graphic_table graphicRef52785" href="/d/graphic/52785.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef50275" href="/d/graphic/50275.html" rel="external">table 4</a> and <a class="graphic graphic_algorithm graphicRef56663" href="/d/graphic/56663.html" rel="external">algorithm 1</a>) and are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6440.html" rel="external">"Emergency department approach to acute-onset psychosis in children", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/6440.html" rel="external">"Emergency department approach to acute-onset psychosis in children", section on 'Approach'</a>.)</p><p>Nystagmus is also a prominent physical finding in children with PCP intoxication. Other toxins that cause nystagmus are listed in the table  (<a class="graphic graphic_table graphicRef74834" href="/d/graphic/74834.html" rel="external">table 2</a>).</p><p>Children without an apparent underlying medical or toxicologic etiology warrant evaluation for psychiatric causes of psychosis. (See  <a class="medical medical_review" href="/d/html/17193.html" rel="external">"Psychosis in adults: Epidemiology, clinical manifestations, and diagnostic evaluation", section on 'Defining features'</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">ANCILLARY STUDIES</span><span class="headingEndMark"> — </span>The diagnosis of PCP intoxication must be suspected clinically. Exposure to PCP is suggested by fluctuating levels of consciousness, psychotic features, nystagmus, and autonomic stimulation.</p><p class="headingAnchor" id="H6403425"><span class="h2">General studies</span><span class="headingEndMark"> — </span>Ancillary studies are obtained to support the clinical diagnosis, evaluate for coingestants, and assess for the presence of rhabdomyolysis and its complications. We recommend the following studies in children and adolescents with altered mental status and suspected PCP intoxication:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid fingerstick blood glucose</strong> – Rapid assessment of blood glucose is essential in all patients with altered mental status. PCP intoxication is associated with hypoglycemia in adults due to excess energy demands. Infants and young children may be predisposed to hypoglycemia after PCP exposure to an even greater degree because of higher turnover of glucose per kilogram of body weight relative to adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum creatine kinase</strong> – Creatine kinase elevation is commonly seen in patients with PCP intoxication and is an important indicator of rhabdomyolysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urine for myoglobin</strong> – Myoglobinuria supports the diagnosis of rhabdomyolysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver enzymes</strong> – Elevations of aspartate transaminase (AST) and alanine transaminase (ALT) are seen in approximately one-half of PCP-intoxicated patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiogram (ECG)</strong> – Conduction abnormalities or arrhythmias may accompany hyperkalemia caused by rhabdomyolysis or may indicate the presence of other cardiotoxic agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum </strong><a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a><strong> (older children and adolescents with risk for intentional overdose)</strong> – Acetaminophen is a common coingestant in the adolescent age group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum salicylate level</strong> – Salicylate toxicity has some features (eg, hyperthermia, altered mental status) that are similar to PCP intoxication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urine pregnancy test (postmenarchal females).</p><p></p><p>Further testing is performed based upon clinical assessment. As examples, blood urea nitrogen and serum creatinine are obtained if rhabdomyolysis or other potential causes of renal failure are suspected, while computed tomography of the head and evaluation of cerebrospinal fluid may be needed in the setting of a persistently altered mental status.</p><p class="headingAnchor" id="H6403279"><span class="h2">Testing for phencyclidine</span><span class="headingEndMark"> — </span>Drug testing for PCP is not necessary in patients who admit to recreational use but may be helpful in patients with an undifferentiated psychosis and to identify inappropriate PCP exposure and initiate necessary social work assessment in victims of child abuse. (See  <a class="medical medical_review" href="/d/html/6440.html" rel="external">"Emergency department approach to acute-onset psychosis in children", section on 'Ancillary studies'</a> and  <a class="medical medical_review" href="/d/html/6600.html" rel="external">"Physical child abuse: Diagnostic evaluation and management", section on 'Toxicology'</a>.)</p><p>Qualitative testing of urine is more helpful than quantitative concentrations since serum levels do not correlate well with brain concentrations or clinical toxicity [<a href="#rid18">18,29</a>]. Confirmatory testing using gas chromatography with mass spectroscopy is performed on rare occasions when definitive drug identification is needed (eg, in cases of suspected child abuse).</p><p>The United States National Institute on Drug Abuse guidelines for federal workplace drug testing use a cutoff urine PCP concentration of 25 ng/mL. Urine toxicology screens may remain positive for several weeks. In one series of chronic users, urine screens remained positive for an average of 14 days [<a href="#rid30">30</a>]. Cerebrospinal fluid testing has been reported in two cases with concentrations one to four times the serum levels [<a href="#rid31">31</a>].</p><p>Multiple causes of false-positive urine tests have been reported, and the potential adverse medicolegal consequences of such results are profound. In one series, the rate of false-positive PCP screens greatly exceeded the rate of true-positive PCP screens [<a href="#rid32">32</a>]. Drugs capable of causing a false-positive urine test include <a class="drug drug_pediatric" data-topicid="13398" href="/d/drug information/13398.html" rel="external">ketamine</a> [<a href="#rid33">33</a>], <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a> [<a href="#rid34">34,35</a>], <a class="drug drug_pediatric" data-topicid="13236" href="/d/drug information/13236.html" rel="external">diphenhydramine</a> [<a href="#rid36">36</a>], <a class="drug drug_pediatric" data-topicid="12878" href="/d/drug information/12878.html" rel="external">venlafaxine</a> [<a href="#rid37">37</a>], <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a> [<a href="#rid38">38</a>], and <a class="drug drug_pediatric" data-topicid="12892" href="/d/drug information/12892.html" rel="external">tramadol</a> [<a href="#rid39">39</a>]. When evaluating a positive qualitative test for PCP, the clinician should consider the clinical presentation and obtain confirmation with gas chromatography and mass spectrophotometry if clinical findings are inconsistent with PCP toxicity. Several PCP derivatives (eg, 3-methoxy-phencyclidine and 4-methoxy phencyclidine) have good cross-reactivity with the PCP screen, meaning the PCP immunoassay may be positive with these drugs, but the test tends to do poorly for other PCP derivatives (eg, methoxetamine or ketamine) [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H24"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Recommendations for care of children and adolescents with PCP intoxication poisoning are derived from case series and reports, including observations in adults, and are driven by physical findings. The treatment of PCP toxicity is primarily supportive.</p><p class="headingAnchor" id="H6404400"><span class="h2">Airway, breathing, and circulation</span><span class="headingEndMark"> — </span>Management of PCP intoxication begins with stabilization of airway, breathing, and circulation. Capillary glucose and pulse oximetry should be determined in patients presenting with altered mental status. A rectal temperature is imperative in agitated or seizing patients to assess for the presence of hyperthermia (rectal temperature &gt;38.5°C [101°F]). Respiratory depression and apnea may occur abruptly in infants and young children necessitating rapid sequence intubation (RSI). We suggest avoiding <a class="drug drug_pediatric" data-topicid="12809" href="/d/drug information/12809.html" rel="external">succinylcholine</a> when performing RSI in patients with known or suspected PCP intoxication who exhibit significant psychomotor agitation or hyperthermia because of the risk of exacerbating rhabdomyolysis-related hyperkalemia. Further acute interventions are based upon clinical findings as quantitative testing for PCP is generally unavailable and unhelpful. (See <a class="local">'Treatment of complications'</a> below.)</p><p>Tachycardia is common but rarely requires specific treatment in children and adolescents.</p><p>Agitated patients warrant careful evaluation for traumatic injuries once adequate sedation is achieved.</p><p class="headingAnchor" id="H6404377"><span class="h2">Sedation</span><span class="headingEndMark"> — </span>Rapid control of psychomotor agitation is the cornerstone of successful management. Physical restraints may be necessary initially and several staff members are often needed to control patients agitated from PCP. Thereafter, chemical sedation is essential to control agitation, prevent or treat hyperthermia, perform a thorough physical examination, and obtain necessary studies.</p><p>Little evidence exists to guide the use of sedatives in the management of PCP intoxication. Based upon observational reports and broad clinical experience, we believe benzodiazepines (eg, <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> 0.1 mg/kg intravenously [IV], typical maximum single dose 4 mg; or <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> 0.1 mg/kg IV, typical maximum single dose 10 mg) are the preferred agents for the initial treatment of PCP-induced agitation. Benzodiazepine dosing may be repeated every 8 to 10 minutes depending upon individual patient response.</p><p class="headingAnchor" id="H6404384"><span class="h3">Severe agitation</span><span class="headingEndMark"> — </span>Early management of agitation or violent behavior is essential to prevent patient and staff injury. The emergency provider should exclude life-threatening hypoglycemia and hypoxia as contributing factors to agitation as soon as is safely possible. We treat severely agitated patients immediately with IV benzodiazepines (<a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> 0.1 mg/kg IV, typical maximum single dose 4 mg; or <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> 0.2 mg/kg IV, typical maximum single dose 10 mg). These doses can be repeated every 8 to 10 minutes based upon patient response. Although IV administration is preferred, intramuscular administration of <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> (0.5 mg/kg, maximum single dose 10 mg) may be given in patients in whom IV access cannot be rapidly achieved.</p><p>Butyrophenones (eg, <a class="drug drug_pediatric" data-topicid="13257" href="/d/drug information/13257.html" rel="external">droperidol</a> or <a class="drug drug_pediatric" data-topicid="13347" href="/d/drug information/13347.html" rel="external">haloperidol</a>) are used as adjunctive therapy in adults with PCP intoxication when benzodiazepines do not adequately control symptoms and in adults with violent behavior due to other causes. (See  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults", section on 'Sedation'</a>.)</p><p>However, young children may be more susceptible to adverse effects of <a class="drug drug_pediatric" data-topicid="13347" href="/d/drug information/13347.html" rel="external">haloperidol</a> (eg, dystonic reaction, seizures). In the United States, <a class="drug drug_pediatric" data-topicid="13257" href="/d/drug information/13257.html" rel="external">droperidol</a> is also subject to a black box warning from the US Food and Drug Administration that recommends it only be used after a 12-lead electrocardiogram (ECG) is obtained and only if other treatments have failed. Furthermore, the warning states that droperidol should be used with <strong>extreme</strong> <strong>caution</strong> in patients who have risk factors for prolonged QT syndrome, are on medications that may prolong the QT interval, or have received IV benzodiazepines.</p><p>Thus, we suggest the following approach in children and adolescents with PCP-induced agitation not responsive to benzodiazepines:</p><p class="bulletIndent1"><span class="glyph">●</span>Butyrophenones should be avoided in infants and children under 12 years of age with PCP intoxication. If agitation is severe and risks life-threatening complications (eg, hyperthermia, rhabdomyolysis), then these patients should undergo RSI and muscle relaxation (ie, paralytic agent)  (<a class="graphic graphic_table graphicRef51456" href="/d/graphic/51456.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13347" href="/d/drug information/13347.html" rel="external">Haloperidol</a> (initial dose 5 mg intramuscularly/IV) may be given to adolescents whose agitation is not controlled with IV benzodiazepines. Some clinicians prefer to avoid butyrophenones because they are purported to lower the seizure threshold and impair heat dissipation in hyperthermic patients. However, there are no high-quality studies in adolescents to support such claims. Furthermore, haloperidol may treat underlying psychotic symptoms that may, in part, be the source of agitation. Patients who receive haloperidol warrant a 12-lead ECG and cardiac monitoring. Adolescents whose agitation persists despite treatment with appropriate doses of benzodiazepines and haloperidol and whose agitation risks life-threatening complications (eg, hyperthermia, rhabdomyolysis) should undergo RSI and muscle relaxation  (<a class="graphic graphic_table graphicRef51456" href="/d/graphic/51456.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When RSI is performed for agitation, <a class="drug drug_pediatric" data-topicid="12809" href="/d/drug information/12809.html" rel="external">succinylcholine</a> should be <strong>avoided</strong> if rhabdomyolysis-induced hyperkalemia is present or highly suspected. (See  <a class="medical medical_review" href="/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care"</a> and  <a class="medical medical_review" href="/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care", section on 'Neuromuscular blocking agents'</a> and  <a class="medical medical_review" href="/d/html/113029.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Medications for sedation and paralysis", section on 'Succinylcholine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest that <a class="drug drug_pediatric" data-topicid="13257" href="/d/drug information/13257.html" rel="external">droperidol</a> <strong>not</strong> be used in children and adolescents with PCP intoxication.</p><p></p><p class="headingAnchor" id="H6404392"><span class="h3">Mild to moderate agitation</span><span class="headingEndMark"> — </span>Patients with mild to moderate agitation should be placed in a quiet environment (darkened, quiet room). We suggest that these patients be given benzodiazepines (<a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> 0.05 mg/kg IV, typical maximum single dose 2 mg; or <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> 0.1 mg/kg IV, typical maximum single dose 5 mg). Oral benzodiazepines (eg, lorazepam 0.1 mg/kg, typical maximum single dose 2 mg) can be given instead of parenteral benzodiazepines to mildly agitated but cooperative patients.</p><p class="headingAnchor" id="H6404407"><span class="h2">Treatment of complications</span><span class="headingEndMark"> — </span>The clinician should anticipate seizures, hyperthermia, rhabdomyolysis, hypertension, and dystonia in children and adolescents with PCP intoxication. Cardiac monitoring and frequent reexamination are essential in patients with any of these complications.</p><p class="headingAnchor" id="H6404487"><span class="h3">Seizures</span><span class="headingEndMark"> — </span>Benzodiazepines (eg, <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a>, initial dose 0.1 mg/kg, maximum single dose 4 mg, repeat in one to two minutes if seizures continue) are the first-line treatment for PCP-induced seizures. If seizures persist despite benzodiazepine administration, administer <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a> (20 mg/kg, maximum initial dose 1 g) or initiate an IV infusion of <a class="drug drug_pediatric" data-topicid="12741" href="/d/drug information/12741.html" rel="external">propofol</a>. Respiratory depression requiring endotracheal intubation and ventilation is typical and should be anticipated  (<a class="graphic graphic_table graphicRef55368" href="/d/graphic/55368.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a>.)</p><p><a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">Phenytoin</a> or <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> is not effective for toxin-induced seizures and should be avoided.</p><p class="headingAnchor" id="H6404583"><span class="h3">Hyperthermia</span><span class="headingEndMark"> — </span>Hyperthermia (rectal temperature &gt;38.5°C [101°F]) may result from PCP-induced myotonic activity, seizures, rhabdomyolysis, or a combination of the three and should be managed aggressively with mechanical cooling measures.</p><p>Augmentation of evaporative cooling is considered the treatment modality of choice because it is effective, noninvasive, and easily performed. The naked patient is sprayed with a mist of lukewarm water while air is circulated with large fans. Shivering may be suppressed with IV benzodiazepines, such as <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> (0.1 mg/kg, maximum single dose 5 mg IV) or <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> (0.05 to 0.1 mg/kg, maximum single dose 1 to 2 mg IV). Cold inspired oxygen, cold gastric lavage, cooling blankets, and cold IV fluids may be helpful adjuncts. (See  <a class="medical medical_review" href="/d/html/6596.html" rel="external">"Heat stroke in children", section on 'Rapid cooling'</a>.)</p><p>Some experts advocate that patients with marked hyperthermia (temperature &gt;40ºC) might benefit from RSI followed by prolonged paralysis to stop heat generation from muscle activity  (<a class="graphic graphic_table graphicRef51456" href="/d/graphic/51456.html" rel="external">table 5</a>). The clinician should <strong>avoid</strong> <a class="drug drug_pediatric" data-topicid="12809" href="/d/drug information/12809.html" rel="external">succinylcholine</a> when performing RSI if hyperkalemia due to rhabdomyolysis is present or highly suspected. (See  <a class="medical medical_review" href="/d/html/113029.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Medications for sedation and paralysis", section on 'Succinylcholine'</a>.)</p><p>There is <strong>no role</strong> for antipyretic agents, such as <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> or <a class="drug drug_pediatric" data-topicid="12829" href="/d/drug information/12829.html" rel="external">aspirin</a>, in the management of drug-induced hyperthermia, since the underlying mechanism does not involve a change in the hypothalamic temperature set-point. Alcohol sponge baths should also be avoided because large amounts of the drug may be absorbed through dilated cutaneous vessels and produce toxicity.</p><p class="headingAnchor" id="H6404788"><span class="h3">Rhabdomyolysis</span><span class="headingEndMark"> — </span>Hyperthermia, agitation, seizures, and muscle rigidity may lead to muscle cell breakdown (rhabdomyolysis) with significant risk for renal failure. Patients with rhabdomyolysis can present with the classic triad of pigmented granular casts in the urine, a red to brown color of the urine supernatant, and a marked elevation in the plasma level of creatine kinase, although rhabdomyolysis is not uncommon in patients whose urine is without visually discernable color change. Primary treatment goals consist of (see  <a class="medical medical_review" href="/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Fluid repletion with normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> infusion (20 to 40 mL/kg per hour up to 1 to 2 L per hour); the emergency provider should closely monitor urine output with the goal of maintaining a minimum urine flow of 4 mL/kg per hour (200 mL per hour in adults). Once diuresis is established with normal saline, alkalinization of the urine is commonly employed but efficacy is uncertain. (See  <a class="medical medical_review" href="/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)", section on 'Bicarbonate in selected patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for significant electrolyte abnormalities (hyperkalemia, hyperphosphatemia, and hypocalcemia); management of hyperkalemia is of particular importance. Hypocalcemia is usually transient, and calcium administration should be avoided unless severe symptoms (eg, tetany) are present.</p><p></p><p class="headingAnchor" id="H6404679"><span class="h3">Hypertension</span><span class="headingEndMark"> — </span>Hypertension is frequently transient, and many patients need no specific treatment. Benzodiazepine administration for agitation is often effective for elevated blood pressure. Because hypertension may primarily reflect alpha adrenergic effects due to decreased reuptake of <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a>, persistent, severe elevations of blood pressure may be treated with <a class="drug drug_pediatric" data-topicid="12648" href="/d/drug information/12648.html" rel="external">nitroprusside</a> or <a class="drug drug_pediatric" data-topicid="12700" href="/d/drug information/12700.html" rel="external">phentolamine</a> (0.1 mg/kg, maximum single dose 5 mg). Pure beta adrenergic blockers are contraindicated because they may cause unopposed accentuation of alpha adrenergic effects with exacerbation of hypertension. (See  <a class="medical medical_review" href="/d/html/3837.html" rel="external">"Evaluation and treatment of hypertensive emergencies in adults", section on 'Sympathetic overactivity resulting in hypertensive emergencies'</a>.)</p><p>Rarely, persistent hypertension in patients with depressed mental status or severe headache may indicate the presence of a subarachnoid hemorrhage with increased intracranial pressure. Such patients should undergo computed tomography of the head and treatment to reduce increased intracranial pressure while maintaining adequate cerebral perfusion pressure. (See  <a class="medical medical_review" href="/d/html/1659.html" rel="external">"Evaluation and management of elevated intracranial pressure in adults", section on 'General management'</a>.)</p><p class="headingAnchor" id="H6404840"><span class="h3">Dystonic reaction</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13236" href="/d/drug information/13236.html" rel="external">Diphenhydramine</a> (1 to 2 mg/kg IV [preferred] or IM, maximum dose 50 mg) or <a class="drug drug_pediatric" data-topicid="13024" href="/d/drug information/13024.html" rel="external">benztropine</a> (0.05 mg/kg IV, maximum single dose 2 mg in children over three years of age) typically provide rapid treatment of a dystonic reaction within minutes of administration. If possible, diphenhydramine should be administered after the urine sample is obtained for toxicologic screening if documentation of PCP intoxication is important because diphenhydramine may cause the specimen to test positive for PCP by immunoassay method [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/315.html" rel="external">"First-generation (typical) antipsychotic medication poisoning", section on 'Acute extrapyramidal syndromes'</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Decontamination</span><span class="headingEndMark"> — </span>Most patients survive PCP intoxication uneventfully with supportive care; decontamination is generally unnecessary in isolated ingestions. However, decontamination with activated charcoal (AC) may be useful if a massive ingestion of PCP or a potentially dangerous coingestant is present and treatment is started within one hour of ingestion. Patients who ingest large amounts of PCP to avoid police detection (body stuffers) or to transport drug for distribution (body packers) may sustain massive ingestions. Any potential benefit from AC must be weighed against the risk of aspiration, especially given the potential for altered mental status and seizures with severe PCP intoxication. AC is given in a dose of 1 g/kg (maximum 50 g). (See  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults", section on 'Decontamination'</a>.)</p><p>The greatest benefit occurs if AC is given within one hour. The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Evidence of efficacy and adverse effects'</a>.)</p><p>Patients who are exposed to PCP should not undergo gastric emptying by gastric lavage or by syrup of ipecac-induced emesis. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Syrup of Ipecac'</a> and  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Gastric lavage'</a>.)</p><p>Patients with PCP intoxication should also not undergo continuous nasogastric suction. Nasogastric suction is theoretically beneficial when performed soon after ingestion due to the high concentration of PCP in the stomach’s acidic environment. However, it has no proven benefit and may cause electrolyte abnormalities, aspiration, and unwanted difficulty in agitated patients.</p><p>Whole bowel irrigation is <strong>not</strong> routinely recommended although it may be used in patients who have ingested potentially lethal amounts of PCP, as may occur with body stuffers or body packers. (See  <a class="medical medical_review" href="/d/html/327.html" rel="external">"Internal concealment of drugs of abuse (body packing)"</a>.)</p><p class="headingAnchor" id="H6404866"><span class="h2">Elimination enhancement</span><span class="headingEndMark"> — </span>We do <strong>not</strong> typically use multidose AC in patients with PCP intoxication. Although PCP undergoes enterohepatic circulation, its typical duration of action is short. Also, there is no evidence of clinical benefit in humans, and the potential for aspiration exists whenever AC is given.</p><p>Neither urine acidification nor charcoal hemoperfusion should be used in the treatment of PCP intoxication. Urinary acidification, in particular, is dangerous as it may worsen renal injury in patients with rhabdomyolysis [<a href="#rid41">41</a>].</p><p>Hemodialysis, which eliminates PCP only from the serum, is ineffective because of the large volume of distribution of the drug (6.2 L/kg).</p><p>Elimination enhancement following PCP intoxication is covered in more detail separately. (See  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults", section on 'Enhanced elimination'</a>.)</p><p class="headingAnchor" id="H1397570"><span class="h2">Antidote</span><span class="headingEndMark"> — </span>The treatment of PCP intoxication is supportive; an effective antidote has not been developed. Anti-PCP Fab fragments have been studied in animals but are not available for use in humans. (See  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults", section on 'Future considerations'</a>.)</p><p class="headingAnchor" id="H1397986"><span class="h2">Child protection</span><span class="headingEndMark"> — </span>Diagnosis of nonrecreational PCP exposure in an infant or young child should prompt involvement of an experienced child protection team (eg, social worker, nurse, subspecialist clinician), if available. In many parts of the world (including the United States, United Kingdom, and Australia), a mandatory report to appropriate government authorities is also required for cases of suspected abuse. (See  <a class="medical medical_review" href="/d/html/6604.html" rel="external">"Child abuse: Social and medicolegal issues", section on 'Mandatory reporting'</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">DISPOSITION</span><span class="headingEndMark"> — </span>Children and adolescents with mild recreational PCP intoxication typically improve rapidly to normal functioning within four to eight hours after exposure. Such patients may be discharged, provided that the effects of intoxication have resolved and the patient remains symptom-free during a brief (one to two hours) period of observation. Prior to discharge, these patients warrant assessment for drug abuse and possible referral to drug rehabilitation. In some adolescents, psychiatric evaluation or referral for concurrent mental illness may also be appropriate.</p><p>Infants and young children with mild PCP intoxication need a full assessment of the social circumstances that led to the exposure. Such an investigation often requires admission.</p><p>Any patient with significant complications (eg, rhabdomyolysis, coma, status epilepticus) or severe symptoms (eg, uncontrolled hypertension, hyperthermia) should be admitted to an intensive care setting. Patients with less severe but persistent symptoms should be admitted to an appropriate inpatient setting for further monitoring and treatment. Return to normal function may take weeks in patients with large ingestions. Severely intoxicated infants have been reported to need 48 hours to 4 days to recover [<a href="#rid12">12</a>].</p><p>As the PCP is eliminated and the intoxication level improves, some adolescent patients may develop psychosis, bizarre behavior, or depression (the so-called "emergence phenomenon") that may last from days to weeks and may require admission for psychiatric treatment, possibly including psychotropic medication [<a href="#rid42">42</a>]. Recovery from psychosis can take weeks to months [<a href="#rid43">43</a>]. Prolonged psychosis occurs more commonly in chronic abusers and is a poor prognostic sign. Withdrawal symptoms, such as depression, anxiety, irritability, restlessness, anergia, and disturbances of thought and sleep, have been described in chronic users after as little as one day of abstinence [<a href="#rid42">42</a>]. Chronic abusers may benefit from behavioral treatment for substance abuse.</p><p class="headingAnchor" id="H106227300"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H3717389"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H2147237286"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114015.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by recreational drug or alcohol use"</a>.)</p><p class="headingAnchor" id="H6404873"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Phencyclidine (PCP) is a dissociative anesthetic that is abused by a significant number of adolescents. PCP exposure is rare in young infants and children and typically represents an inadvertent oral or inhalational exposure due to caregiver drug use. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – PCP intoxication produces a wide range of vital sign and neuropsychiatric findings. In infants and young children, altered mental status (eg, lethargy, irritability), nystagmus, choreoathetosis, seizures, ataxia, and blank staring are common features. Abrupt respiratory depression with apnea may occur. In adolescents, nystagmus, psychomotor agitation, hallucinations, and violent behavior are prevalent. (See <a class="local">'Clinical features of overdose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The clinical picture of PCP intoxication shares features common to many other intoxications and medical conditions, especially those that cause acute psychosis. The differential diagnosis and approach to acute psychosis in the emergency department is provided in the tables and algorithm  (<a class="graphic graphic_table graphicRef52785" href="/d/graphic/52785.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef50275" href="/d/graphic/50275.html" rel="external">table 4</a> and <a class="graphic graphic_algorithm graphicRef56663" href="/d/graphic/56663.html" rel="external">algorithm 1</a>) and is discussed in detail separately. (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/6440.html" rel="external">"Emergency department approach to acute-onset psychosis in children", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/6440.html" rel="external">"Emergency department approach to acute-onset psychosis in children", section on 'Approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ancillary studies – </strong>Ancillary studies obtained to support the clinical diagnosis, evaluate for co-ingestants, and assess for the presence of rhabdomyolysis and its complications are discussed above. (See <a class="local">'General studies'</a> above.)</p><p></p><p class="bulletIndent1">Quantitative drug levels have little role in the management of acute toxicity of known recreational drug users. Qualitative urine testing is appropriate when distinguishing acute psychosis due to drug toxicity from other types of psychosis and in situations where child abuse is suspected. Results may remain positive for weeks. Thus, a positive urine test m<strong>ay not</strong> indicate acute intoxication. (See <a class="local">'Testing for phencyclidine'</a> above and  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults", section on 'Testing for PCP'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Treatment of PCP intoxication is primarily supportive. In addition to careful assessment and support of airway, breathing, and circulation, as needed, the clinician should anticipate and aggressively manage agitation, seizures, hyperthermia, rhabdomyolysis, hypertension, and dystonic reactions. (See <a class="local">'Airway, breathing, and circulation'</a> above and <a class="local">'Sedation'</a> above and <a class="local">'Treatment of complications'</a> above.)</p><p></p><p class="bulletIndent1">Early management of agitation or violent behavior is essential to prevent patient and staff injury. Sedation should be administered as rapidly as possible. The emergency provider should exclude life-threatening hypoglycemia and hypoxia as contributing factors to agitation as soon as is safely possible. Our approach to sedation is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe agitation</strong> – In a severely agitated child or adolescent, we suggest immediately administering an intravenous (IV) benzodiazepine (<a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> 0.1 mg/kg IV, typical maximum single dose 4 mg; or <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> 0.2 mg/kg IV, typical maximum single dose 10 mg) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). These doses can be repeated every 8 to 10 minutes based upon patient response. Although IV administration is preferred, intramuscular administration of <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> (0.5 mg/kg, typical maximum single dose 10 mg) may be given in patients in whom IV access cannot be rapidly achieved. (See <a class="local">'Severe agitation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe agitation not responding to benzodiazepines</strong> – In an adolescent patient with severe agitation that threatens harm to themselves or others and is not controlled with parenteral benzodiazepines, we suggest administering parenteral <a class="drug drug_pediatric" data-topicid="13347" href="/d/drug information/13347.html" rel="external">haloperidol</a> (initial dose 5 mg, IV or intramuscularly) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). An adolescent whose agitation persists despite treatment with appropriate doses of benzodiazepines and haloperidol and whose agitation risks life-threatening complications (eg, hyperthermia, rhabdomyolysis) should undergo rapid sequence intubation (RSI) and muscle relaxation (ie, paralytic agent)  (<a class="graphic graphic_table graphicRef51456" href="/d/graphic/51456.html" rel="external">table 5</a>). (See <a class="local">'Severe agitation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe intoxication with risk for hyperthermia or rhabdomyolysis</strong> – In an infant or child under 12 years of age with severe PCP intoxication that risks life-threatening complications (eg, hyperthermia, rhabdomyolysis), we suggest performing RSI and muscle relaxation (ie, paralytic agent)  (<a class="graphic graphic_table graphicRef51456" href="/d/graphic/51456.html" rel="external">table 5</a>) rather than administering <a class="drug drug_pediatric" data-topicid="13347" href="/d/drug information/13347.html" rel="external">haloperidol</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Severe agitation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild or moderate intoxication</strong> – In a patient with mild or moderate PCP intoxication, we suggest administering a benzodiazepine (eg, <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> 0.05 mg/kg IV, typical maximum single dose 2 mg; or <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> 0.1 mg/kg IV, typical maximum single dose 5 mg) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The benzodiazepine may be repeated as needed. (See <a class="local">'Mild to moderate agitation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of gastrointestinal decontamination –</strong> Children and adolescents with PCP intoxication should <strong>not</strong> undergo gastric emptying (induced vomiting or gastric lavage) or continuous nasogastric suctioning. Children and adolescents with isolated PCP intoxication should also <strong>not</strong> receive activated charcoal (AC). However, patients with coingestants that bind to AC may benefit from its administration. (See <a class="local">'Decontamination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Child protection</strong> – Diagnosis of PCP exposure in an infant or young child should prompt involvement of an experienced child protection team (eg, social worker, nurse, subspecialist clinician), if available, and mandatory reporting, depending on the local legal requirements. Infants and young children with mild PCP intoxication need a full assessment of the social circumstances that allowed the exposure. Such an investigation often requires admission. (See <a class="local">'Child protection'</a> above and  <a class="medical medical_review" href="/d/html/6604.html" rel="external">"Child abuse: Social and medicolegal issues", section on 'Mandatory reporting'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disposition </strong>– Patients of any age with persistent symptoms should be admitted to a monitored setting. Due to the relatively short duration of action, older children and adolescents with mild symptoms are candidates for a period of observation and discharge. Patients whose medical symptoms resolve but have persistent behavioral issues should receive psychiatric evaluation. (See <a class="local">'Disposition'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Pali MJ, Tharratt RS, Albertson TE. Phencyclidine and its congeners. In: Critical Care Toxicology, 1st, Brent J, Wallace KL, Burkhart KK, et al (Eds), Mosby, Philadelphia 2005. p.777.</li><li><a class="nounderline abstract_t">CHEN G, ENSOR CR, RUSSELL D, BOHNER B. The pharmacology of 1-(1-phenylcyclohexyl) piperidine-HCl. J Pharmacol Exp Ther 1959; 127:241.</a></li><li><a class="nounderline abstract_t">Wright HH, Cole EA, Batey SR, Hanna K. Phencyclidine-induced psychosis: eight-year follow-up of ten cases. South Med J 1988; 81:565.</a></li><li class="breakAll">National Institute on Drug Abuse. Monitoring the Future. https://www.drugabuse.gov/drug-topics/trends-statistics/monitoring-future.</li><li class="breakAll">Drug Abuse Warning Network, 2008: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Office of Applied Studies, SAMHSA, 2009. https://dawninfo.samhsa.gov/data/ (Accessed on October 20, 2010).</li><li class="breakAll">Bush DM. Emergency department visits involving phencyclidine (PCP). The CBHSQ Report. Substance Abuse and Mental Health Administration; Rockville, MD, 2013.</li><li><a class="nounderline abstract_t">Poklis A, Graham M, Maginn D, et al. Phencyclidine and violent deaths in St. Louis, Missouri: a survey of medical examiners' cases from 1977 through 1986. Am J Drug Alcohol Abuse 1990; 16:265.</a></li><li><a class="nounderline abstract_t">Welch MJ, Correa GA. PCP intoxication in young children and infants. Clin Pediatr (Phila) 1980; 19:510.</a></li><li><a class="nounderline abstract_t">Shesser R, Jotte R, Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med 1991; 9:336.</a></li><li class="breakAll">Liang IV, Boyer EW. Dissociative agents: Phencyclidine, ketamine, and dextromethorphan. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th, Shannon MW, Borron SW, Burns MJ (Eds), Saunders Elsevier, Philadelphia 2007. p.773.</li><li><a class="nounderline abstract_t">Karp HN, Kaufman ND, Anand SK. Phencyclidine poisoning in young children. J Pediatr 1980; 97:1006.</a></li><li><a class="nounderline abstract_t">Schwartz RH, Einhorn A. PCP intoxication in seven young children. Pediatr Emerg Care 1986; 2:238.</a></li><li><a class="nounderline abstract_t">McDonald JW, Johnston MV. Excitatory amino acid neurotoxicity in the developing brain. NIDA Res Monogr 1993; 133:185.</a></li><li class="breakAll">Omedo RE. Phencyclidine and ketamine. In: Goldfrank's Toxicologic Emergencies, 10th edition, Hoffman RS, Howland MA, Lewin NA, et al (Eds), McGraw Hill Education, New York 2015. p.1144.</li><li><a class="nounderline abstract_t">Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301.</a></li><li><a class="nounderline abstract_t">Akunne HC, Reid AA, Thurkauf A, et al. [3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex. Synapse 1991; 8:289.</a></li><li><a class="nounderline abstract_t">Wolfe SA Jr, De Souza EB. Sigma and phencyclidine receptors in the brain-endocrine-immune axis. NIDA Res Monogr 1993; 133:95.</a></li><li><a class="nounderline abstract_t">Barton CH, Sterling ML, Vaziri ND. Phencyclidine intoxication: clinical experience in 27 cases confirmed by urine assay. Ann Emerg Med 1981; 10:243.</a></li><li><a class="nounderline abstract_t">Tahir H, Daruwalla V. Phencyclidine Induced Oculogyric Crisis Responding Well to Conventional Treatment. Case Rep Emerg Med 2015; 2015:506301.</a></li><li><a class="nounderline abstract_t">Seiden JA, Mittal MK. An infant with obtundation and tongue thrusting. Phencyclidine poisoning. Pediatr Emerg Care 2008; 24:629.</a></li><li><a class="nounderline abstract_t">McCarron MM, Schulze BW, Thompson GA, et al. Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med 1981; 10:237.</a></li><li><a class="nounderline abstract_t">Kaufman KR, Petrucha RA, Pitts FN Jr, Kaufman ER. Phencyclidine in umbilical cord blood: preliminary data. Am J Psychiatry 1983; 140:450.</a></li><li><a class="nounderline abstract_t">Kaufman KR, Petrucha RA, Pitts FN Jr, Weekes ME. PCP in amniotic fluid and breast milk: case report. J Clin Psychiatry 1983; 44:269.</a></li><li><a class="nounderline abstract_t">Chasnoff IJ, Burns WJ, Hatcher RP, Burns KA. Phencyclidine: effects on the fetus and neonate. Dev Pharmacol Ther 1983; 6:404.</a></li><li><a class="nounderline abstract_t">Strauss AA, Modaniou HD, Bosu SK. Neonatal manifestations of maternal phencyclidine (PCP) abuse. Pediatrics 1981; 68:550.</a></li><li><a class="nounderline abstract_t">Golden NL, Sokol RJ, Rubin IL. Angel dust: possible effects on the fetus. Pediatrics 1980; 65:18.</a></li><li><a class="nounderline abstract_t">Rahbar F, Fomufod A, White D, Westney LS. Impact of intrauterine exposure to phencyclidine (PCP) and cocaine on neonates. J Natl Med Assoc 1993; 85:349.</a></li><li><a class="nounderline abstract_t">Ali SF, Ahmad G, Slikker W Jr, Bondy SC. Effects of gestational exposure to phencyclidine: distribution and neurochemical alterations in maternal and fetal brain. Neurotoxicology 1989; 10:383.</a></li><li><a class="nounderline abstract_t">Bailey DN. Phencyclidine abuse. Clinical findings and concentrations in biological fluids after nonfatal intoxication. Am J Clin Pathol 1979; 72:795.</a></li><li><a class="nounderline abstract_t">Simpson GM, Khajawall AM, Alatorre E, Staples FR. Urinary phencyclidine excretion in chronic abusers. J Toxicol Clin Toxicol 1982; 19:1051.</a></li><li><a class="nounderline abstract_t">Donaldson JO, Baselt RC. CSF phencyclidine. Am J Psychiatry 1979; 136:1341.</a></li><li><a class="nounderline abstract_t">Johnson-Davis KL, Sadler AJ, Genzen JR. A Retrospective Analysis of Urine Drugs of Abuse Immunoassay True Positive Rates at a National Reference Laboratory. J Anal Toxicol 2016; 40:97.</a></li><li><a class="nounderline abstract_t">Hoffman RJ, Saddock V, Nelson L. Effect of ketamine on phencyclidine immunoassays (abstract). J Toxicol Clin Toxicol 2001; 39:523.</a></li><li><a class="nounderline abstract_t">Budai B, Iskandar H. Dextromethorphan can produce false positive phencyclidine testing with HPLC. Am J Emerg Med 2002; 20:61.</a></li><li><a class="nounderline abstract_t">Schier J. Avoid unfavorable consequences: dextromethorpan can bring about a false-positive phencyclidine urine drug screen. J Emerg Med 2000; 18:379.</a></li><li><a class="nounderline abstract_t">Levine BS, Smith ML. Effects of diphenhydramine on immunoassays of phencyclidine in urine. Clin Chem 1990; 36:1258.</a></li><li><a class="nounderline abstract_t">Santos PM, López-García P, Navarro JS, et al. False positive phencyclidine results caused by venlafaxine. Am J Psychiatry 2007; 164:349.</a></li><li><a class="nounderline abstract_t">Geraci MJ, Peele J, McCoy SL, Elias B. Phencyclidine false positive induced by lamotrigine (Lamictal®) on a rapid urine toxicology screen. Int J Emerg Med 2010; 3:327.</a></li><li><a class="nounderline abstract_t">Hull MJ, Griggs D, Knoepp SM, et al. Postmortem urine immunoassay showing false-positive phencyclidine reactivity in a case of fatal tramadol overdose. Am J Forensic Med Pathol 2006; 27:359.</a></li><li><a class="nounderline abstract_t">Gomila I, Leciñena MÁ, Elorza MÁ, et al. Detectability of Dissociative Psychoactive Substances in Urine by Five Commercial Phencyclidine Immunoassays. J Anal Toxicol 2019; 43:497.</a></li><li><a class="nounderline abstract_t">Patel R, Connor G. A review of thirty cases of rhabdomyolysis-associated acute renal failure among phencyclidine users. J Toxicol Clin Toxicol 1985-1986; 23:547.</a></li><li><a class="nounderline abstract_t">Rappolt RT Sr, Gay GR, Farris RD. Phencyclidine (PCP) intoxication: diagnosis in stages and algorithms of treatment. Clin Toxicol 1980; 16:509.</a></li><li><a class="nounderline abstract_t">Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1978; 135:1081.</a></li></ol></div><div id="topicVersionRevision">Topic 6506 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pali MJ, Tharratt RS, Albertson TE. Phencyclidine and its congeners. In: Critical Care Toxicology, 1st, Brent J, Wallace KL, Burkhart KK, et al (Eds), Mosby, Philadelphia 2005. p.777.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13809587" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The pharmacology of 1-(1-phenylcyclohexyl) piperidine-HCl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3368805" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Phencyclidine-induced psychosis: eight-year follow-up of ten cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3368805" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Phencyclidine-induced psychosis: eight-year follow-up of ten cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3368805" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Phencyclidine-induced psychosis: eight-year follow-up of ten cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3368805" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Phencyclidine-induced psychosis: eight-year follow-up of ten cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2288325" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Phencyclidine and violent deaths in St. Louis, Missouri: a survey of medical examiners' cases from 1977 through 1986.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7389238" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : PCP intoxication in young children and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2054004" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The contribution of impurities to the acute morbidity of illegal drug use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2054004" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The contribution of impurities to the acute morbidity of illegal drug use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7441408" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Phencyclidine poisoning in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3797269" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : PCP intoxication in seven young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232513" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Excitatory amino acid neurotoxicity in the developing brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232513" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Excitatory amino acid neurotoxicity in the developing brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1654746" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Recent advances in the phencyclidine model of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1833849" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : [3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232518" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sigma and phencyclidine receptors in the brain-endocrine-immune axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7224272" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Phencyclidine intoxication: clinical experience in 27 cases confirmed by urine assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26101673" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Phencyclidine Induced Oculogyric Crisis Responding Well to Conventional Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18797376" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : An infant with obtundation and tongue thrusting. Phencyclidine poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7224271" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6837783" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Phencyclidine in umbilical cord blood: preliminary data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6863228" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : PCP in amniotic fluid and breast milk: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6641470" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Phencyclidine: effects on the fetus and neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7322687" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Neonatal manifestations of maternal phencyclidine (PCP) abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7355023" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Angel dust: possible effects on the fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8496988" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impact of intrauterine exposure to phencyclidine (PCP) and cocaine on neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2576301" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects of gestational exposure to phencyclidine: distribution and neurochemical alterations in maternal and fetal brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/506993" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Phencyclidine abuse. Clinical findings and concentrations in biological fluids after nonfatal intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7184997" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Urinary phencyclidine excretion in chronic abusers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/484738" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : CSF phencyclidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26668238" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A Retrospective Analysis of Urine Drugs of Abuse Immunoassay True Positive Rates at a National Reference Laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of ketamine on phencyclidine immunoassays (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781921" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dextromethorphan can produce false positive phencyclidine testing with HPLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10787303" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Avoid unfavorable consequences: dextromethorpan can bring about a false-positive phencyclidine urine drug screen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2357810" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effects of diphenhydramine on immunoassays of phencyclidine in urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267806" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : False positive phencyclidine results caused by venlafaxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21373301" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Phencyclidine false positive induced by lamotrigine (Lamictal®) on a rapid urine toxicology screen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133040" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Postmortem urine immunoassay showing false-positive phencyclidine reactivity in a case of fatal tramadol overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31329888" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Detectability of Dissociative Psychoactive Substances in Urine by Five Commercial Phencyclidine Immunoassays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3831378" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A review of thirty cases of rhabdomyolysis-associated acute renal failure among phencyclidine users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7408426" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Phencyclidine (PCP) intoxication: diagnosis in stages and algorithms of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/696930" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Phencyclidine-induced psychosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
